KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Goodwill (2016 - 2025)

Pacira BioSciences has reported Goodwill over the past 14 years, most recently at $20.2 million for Q4 2025.

  • Quarterly results put Goodwill at $20.2 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $20.2 million (changed N/A YoY), and the annual figure for FY2025 was $20.2 million, changed.
  • Goodwill for Q4 2025 was $20.2 million at Pacira BioSciences, down from $20.3 million in the prior quarter.
  • Over the last five years, Goodwill for PCRX hit a ceiling of $163.2 million in Q4 2022 and a floor of $20.2 million in Q4 2025.
  • Median Goodwill over the past 5 years was $145.9 million (2022), compared with a mean of $117.7 million.
  • Biggest five-year swings in Goodwill: skyrocketed 58.19% in 2022 and later plummeted 87.56% in 2025.
  • Pacira BioSciences' Goodwill stood at $145.2 million in 2021, then grew by 12.43% to $163.2 million in 2022, then changed by 0.0% to $163.2 million in 2023, then changed by 0.0% to $163.2 million in 2024, then plummeted by 87.62% to $20.2 million in 2025.
  • The last three reported values for Goodwill were $20.2 million (Q4 2025), $20.3 million (Q3 2025), and $20.3 million (Q2 2025) per Business Quant data.